Published in Hepatitis Weekly, April 26th, 1999
These in vivo data support earlier laboratory results indicating that adefovir remains active against lamivudine-resistant HBV, the company says.
"HBV resistance to lamivudine occurs in 14 to 30 percent of patients with chronic HBV who have been treated for one year and becomes even more common after 24 months of therapy," said clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly